ERBB2 and cancer: Consistent with these observations, we hypothesized that the transmembrane FA transporter CD36 could be increased as an adaptive lipid metabolic response to guarantee FAs supply and accumulation within cancer cells when the HER2/FASN oncometabolic PFL is inhibited by anti-HER2 treatments.